Draft regs bolster IP protections for newly approved drugs
Subscribe to keep reading.
Trivium Tech keeps you briefed on the latest developments in China tech policy.
Already a subscriber? Log in.
China wants companies to sell more and newer drugs.
On Wednesday, China’s drug regulator (NMPA) released draft rules on the protection of drug trial data.
If passed as written, data submitted to NMPA as part of the drug approval process would be protected for up to six years.
Some context: Develo...